Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records.

Breast cancer research and treatment - 1 Apr 2023

Thorén Linda, Margolin Sara, Eliasson Erik, Bergh Jonas, Lindh Jonatan D

Abstract excerpt

PURPOSE: Suboptimal adherence to adjuvant endocrine treatment (AET) is an important clinical concern. A correlation between CYP2D6 activity and tamoxifen discontinuation has been described. The main aim of this study was to investigate the consistency between pharmacy dispensation data and medical records on adherence to AET. METHODS: Adherence was calculated for patients with at least 4.5 years of follow up and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Aromatase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Chemotherapy, Adjuvant

Share to Cytochrome P-450 CYP2D6

Share to Genotype

Share to Medical Records

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 36856936
DOI: 10.1007/s10549-023-06887-2
PMCID: PMC10036436

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records.PMID 36856936Read ↗

CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.Semantic proximity Read ↗

CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer.Semantic proximity Read ↗

CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.Semantic proximity Read ↗

Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.Semantic proximity Read ↗

Assessment of compliance with hormonal therapy in early breast cancer patients with positive hormone receptor phenotype: A single institution study.Semantic proximity Read ↗

Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.Semantic proximity Read ↗

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.Semantic proximity Read ↗

Persistence with oral bisphosphonates and denosumab among older adults in primary care in IrelandSemantic proximity Read ↗

Prescription and Safety of Oral Antidiabetic Drugs in Outpatients with Type 2 Diabetes Mellitus: The Role Adherence in a Real-Life Primary Care SettingSemantic proximity Read ↗

Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.Semantic proximity Read ↗

Methodological issues in electronic healthcare database studies of drug cancer associations : identification of cancer, and drivers of discrepant resultsSemantic proximity Read ↗

Adherence to escitalopram treatment in depression: a study of electronically compiled dosing histories in the 'Depression: the search for phenotypes' study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.